Table 1 Characteristics of the included studies

Charles S. Fuchs

Ram

2014

3

2

Ram + BSC

238

60

5.20

2.10

49

3

Placebo + BSC

117

60

3.80

1.30

23

3

P = 0.76

P < 0.0001

Hansjochen Wilke

Ram

2014

3

2

Ram + PTX

330

61

9.60

4.40

80

28

Placebo + PTX

335

61

7.40

2.90

64

16

P < 0.0001

P = 0.0001

Harry H.

Ram

2014

2

1

Ram + mFOLFOX6

84

65

6.40

11.70

85

45

Placebo + mFOLFOX6

84

60

6.70

11.50

67

46

P = 0.008

Jin Li

Apatinib

2013

2

>2

Apatinib

47

55

4.83

3.67

7.32

6.38

Apatinib

46

53

4.27

3.20

15

13.04

Placebo

48

54

2.50

1.40

0

0

Shukui Qin

Apatinib

2016

3

>2

Apatinib

176

58

6.50

2.60

42.05

2.84

Placebo

91

58

4.70

1.80

8.79

0

P = 0.1695

P < 0.001

Atsushi Ohtsu

Bev

2011

3

1

Bev + CDP + Cap

387

58

12.10

6.70

76.9

46

Placebo + CDP + Cap

387

59

10.10

5.30

67.7

37.4

P = 0.0315

Lin Shen

Bev

2015

3

1

Bev + CDP + Cap

100

54.2

10.50

6.30

75.3

41

Placebo + CDP + Cap

102

55.5

11.40

6.00

72.1

34

P = 0.35

Markus Hermann Moehler

Sunitinib

2013

2

2

Sunitinib + FOLFIRI

45

NR

10.50

3.60

58

20

Placebo + FOLFIRI

46

NR

9.00

3.30

56

29

JH Yi

Sunitinib

2012

2

2

Sunitinib + docetaxel

56

54

8.00

3.90 (TTP)

75

41.1

Docetaxel

49

52

6.60

2.60 (TTP)

51

14.3

W Koizumi

TSU-68

2013

2

1

TSU-68 + S-1/CDDP

45

62

16.6

6.9

NR

62.2

S-1/CDDP

46

63.5

15.45

7.1

NR

56.5